Manu Chakravarthy
Hoofd Techniek/Wetenschap/O&O bij Carmot Therapeutics, Inc.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Heather Turner | F | 51 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 jaar |
Timothy Kutzkey | M | 49 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 14 jaar |
Stig Hansen | M | 59 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 16 jaar |
Minako Pazdera | M | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 jaar |
Charles Newton | M | 53 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 jaar |
Kelly Boothe | M | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | - |
Aetna Wun Trombley | M | 45 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 8 jaar |
Jamere Jackson | M | 54 | 8 jaar | |
Timothy Garnett | M | 63 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 jaar |
Anne Phillips | M | 70 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 jaar |
Timothy Garnett | - | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 jaar |
Peter Svennilson | M | 62 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 4 jaar |
Michael Gray | M | 53 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 jaar |
Juan Luciano | M | 62 | 8 jaar | |
David H. Schubert | M | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | - |
Johna Norton | F | 57 | 7 jaar | |
Heidi Brumbach | F | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 jaar |
LeAnne Stewart | F | 59 |
Saint John's University
| 29 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
John Lechleiter | M | 70 | 38 jaar | |
Shreeram Aradhye | M | 62 | 3 jaar | |
Robert Connelly | M | 63 | 5 jaar | |
William Hinshaw | M | 55 | 5 jaar | |
Paul Fehlner | M | 61 | 5 jaar | |
Karen N. Horn | M | 80 | 29 jaar | |
Franklyn Prendergast | M | 79 | 22 jaar | |
Chip Baird | M | 52 | 5 jaar | |
Joshua Smiley | M | 54 | 5 jaar | |
Heidy Abreu King-Jones | F | 41 | - | |
Shane Maltbie | M | 42 | 4 jaar | |
Catherine Sohn | M | 71 | 4 jaar | |
Jason Fredette | M | - | - | |
Derica Rice | M | 59 | 14 jaar | |
Christopher Viehbacher | M | 64 | 4 jaar | |
Carolyn Bertozzi | M | 57 | 4 jaar | |
Cristina Rondinone | M | 64 | 5 jaar | |
Noubar Afeyan | M | 60 | 9 jaar | |
Margaret Koziel | M | 64 | 4 jaar | |
Stephen Mitchener | M | 45 | 2 jaar | |
Tony Tramontin | M | 56 | 3 jaar | |
Sheena Aurora | M | - | 4 jaar | |
Stephen Curtis | M | - | 1 jaar | |
Thomas W. Grein | M | 72 | 41 jaar | |
Karen Lewis | F | - | 1 jaar | |
Lori Macomber | F | 53 | 7 jaar | |
Gary He | M | - | 12 jaar | |
Jeremy Morgan | M | - | 3 jaar | |
Anthony Iannazzo | M | - |
Saint John's University
| 4 jaar |
Erika Jones | F | 39 | 3 jaar | |
Trafford Clarke | M | 66 | - | |
Jane Smith | F | - | 3 jaar | |
Wen Hao Wang | M | 51 |
Saint John's University
| 4 jaar |
Richard Gaynor | M | 74 | 14 jaar | |
Michael Andriole | M | 51 | 16 jaar | |
John Russo Tieri | M | - |
Saint John's University
| 5 jaar |
Derek Schoenhofen | M | - |
Saint John's University
| 4 jaar |
Charles Cooney | M | 80 | 7 jaar | |
Peter Hutt | M | 89 | 4 jaar | |
Thomas Fred Musmanno | M | 55 |
Saint John's University
| 2 jaar |
Laurent Chardonnet | M | 59 | 2 jaar | |
Patricia Martin | F | 63 | 26 jaar | |
Fionnuala M. Walsh | M | 64 | 29 jaar | |
David Epstein | M | 62 | 5 jaar | |
Bronwen Mantlo | M | - | 4 jaar | |
Barton Peterson | M | 65 | 8 jaar | |
Jullian Jones | M | - | 4 jaar | |
Rachel Humphrey | M | 62 | - | |
Levi Garraway | M | - | 2 jaar | |
Ivana Magovcevic-Liebisch | M | 55 | 1 jaar | |
Christi L. Shaw | F | 57 | 2 jaar | |
Jim Stellakis | M | - |
Saint John's University
| 4 jaar |
Thomas Leggett | M | 47 | 2 jaar | |
Mark Andersen | M | 53 | 11 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 72 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Manu Chakravarthy
- Persoonlijk netwerk